EPRX
Eupraxia Pharmaceuticals Inc

138
Mkt Cap
$388.81M
Volume
45,928.00
52W High
$7.19
52W Low
$2.50
PE Ratio
-6.43
EPRX Fundamentals
Price
$5.44
Prev Close
$5.61
Open
$5.58
50D MA
$5.63
Beta
0.29
Avg. Volume
182,349.38
EPS (Annual)
-$0.7516
P/B
-21.38
Loading...
Loading...
News
all
press releases
Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year?
Here is how Elanco Animal Health Incorporated (ELAN) and Eupraxia Pharmaceuticals Inc. (EPRX) have performed compared to their sector so far this year.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
Does Eupraxia Pharmaceuticals Inc. (EPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·16d ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
Eupraxia Pharmaceuticals Inc. (EPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·16d ago
News Placeholder
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
The consensus price target hints at an 85.1% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·16d ago
News Placeholder
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE...
PR Newswire·8mo ago
News Placeholder
Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia Pharmaceuticals Announces CFO Succession Eupraxia Pharmaceuticals Announces CFO Succession PR Newswire VICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell...
PR Newswire·8mo ago
News Placeholder
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months Eupraxia's DiffuSphere Technology Demonstrates Targeted...
PR Newswire·11mo ago
News Placeholder
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual...
PR Newswire·1y ago
News Placeholder
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 Eupraxia...
PR Newswire·1y ago
News Placeholder
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Eupraxia Pharmaceuticals Announces Positive Data...
PR Newswire·1y ago

Latest EPRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.